Income Statement
ELICIO THERAPEUTICS, INC.
ELTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | 2.30 | 28.31 |
|
Cost of Revenue
|
- | - | - | 0.00 | 0.43 |
|
Gross Profit
|
- | - | - | 2.30 | 27.88 |
|
Operating Expenses
|
37.71 | 44.99 | 35.75 | 32.74 | 67.19 |
|
Research & Development
|
24.90 | 33.66 | 23.85 | 18.10 | 48.70 |
|
Selling, General & Administrative
|
12.81 | 11.33 | 11.90 | 14.64 | 18.49 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-37.71 | -44.99 | -35.75 | -30.44 | -39.31 |
|
Non-Operating Income
|
-1.86 | -6.91 | 0.55 | 0.81 | -15.27 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
0.10 | 0.20 | 1.06 | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | 0.15 | -0.10 |
|
Income Before Tax
|
-39.57 | - | - | -38.80 | -54.57 |
|
Income Tax Expense
|
0.00 | 0.00 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-39.57 | -51.90 | -35.20 | -38.81 | -54.57 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-37.71 | -44.99 | -35.75 | -30.44 | -39.31 |
|
Earnings Per Share (Basic)
|
-2.58 | -4.25 | -6.96 | -1.29 | -1.93 |
|
Diluted EPS
|
-2.58 | -4.25 | -6.96 | -1.29 | -1.93 |
|
Weighted Average Shares
|
15.31 | 12.20 | 5.06 | 30.04 | 28.24 |
|
Diluted Weighted Avg Shares
|
15.31 | 12.20 | 5.06 | 30.04 | 28.24 |
|
Comprehensive Income
|
-39.52 | -51.88 | -35.39 | -38.62 | -54.34 |